cefoxitin and Lung-Abscess

cefoxitin has been researched along with Lung-Abscess* in 4 studies

Trials

2 trial(s) available for cefoxitin and Lung-Abscess

ArticleYear
Evaluation of cefoxitin sodium therapy in anaerobic infections.
    The Journal of antimicrobial chemotherapy, 1978, Volume: 4, Issue:B

    Topics: Adult; Anaerobiosis; Bacterial Infections; Cefoxitin; Cephalosporins; Clinical Trials as Topic; Female; Humans; Liver Abscess; Lung Abscess; Male; Osteomyelitis

1978
Clinical experience with cefoxitin sodium.
    The Journal of antimicrobial chemotherapy, 1978, Volume: 4, Issue:B

    Topics: Arthritis; Bacterial Infections; Cefoxitin; Cephalosporins; Clinical Trials as Topic; Empyema, Tuberculous; Endocarditis, Bacterial; Humans; Lung Abscess; Osteomyelitis; Pneumonia; Sepsis; Urinary Tract Infections

1978

Other Studies

2 other study(ies) available for cefoxitin and Lung-Abscess

ArticleYear
[Clinical studies of cefoxitin with special reference to pulmonary suppuration and pyothorax with respiratory tract infection].
    The Japanese journal of antibiotics, 1984, Volume: 37, Issue:9

    Cefoxitin (CFX) was administered to 12 patients with respiratory tract infections, including mainly patients with pulmonary suppuration or pyothorax. The results were as follows: CFX was effective in 75% of the total patients, and in 83% of the 6 patients with pulmonary suppuration or pyothorax. Microorganisms which were considered to be causative were isolated in 8 of 12 patients. Bacteriological responses were "eradicated" in 4 patients, "replaced" in 3 patients, "unchanged" in 1 patient. A slight elevation of S-GPT was observed in one patient and elevation of A1-P in another following CFX administration; however, these values returned to normal shortly after completion of drug administration. No adverse effects, allergic symptoms or laboratory abnormalities were observed.

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Cefoxitin; Drug Evaluation; Empyema; Female; Humans; Infusions, Parenteral; Lung Abscess; Male; Middle Aged; Respiratory Tract Infections

1984
Clinical and experimental evaluation of cefoxitin therapy.
    Chemotherapy, 1979, Volume: 25, Issue:4

    30 patients were treated with i.v. cefoxitin (4-8 g/day), of which 20 had documented infections which included endocarditis (5), lung abscess (4), empyema (4), liver and subhepatic abscess (3), osteomyelitis (3), and pancreatic abscess (1). 14 patients had infections caused by anaerobic bacteria and 5 had endocarditis due to aerobic organisms. All but 2 patients with osteomyelitis of the mandible were cured. Adverse reactions were noted in 7 patients, mostly due to drug fever and leukocytosis; one had Coombs'-positive hemolytic anemia. The average serum cefoxitin levels were 24, 16, 12, and 4 microgram/ml at 1, 2, 3 and 4 h, respectively, and the average serum/pleural fluid ratio was 1:0.5 +/- 0.25. All anaerobic and aerobic isolates except one strain of Bacteroides fragilis were susceptible to cefoxitin at less than or equal to 32 microgram/ml. The concentration of cefoxitin in the tissues was measured in 8 rabbits; it was 4 +/- 1 microgram/ml in the heart and 2 +/- 0.5 microgram/ml in the femur and mandibular tissue, suggesting that the lack of response in cases of osteomyelitis could be due to inadequate antibiotic concentration in the bone. Our study suggests that cefoxitin can be used in the treatment of anaerobic infections and endocarditis due to susceptible organisms.

    Topics: Abscess; Adult; Animals; Bacterial Infections; Bacteriological Techniques; Cefoxitin; Cephalosporins; Drug Evaluation; Empyema; Endocarditis, Bacterial; Female; Humans; Liver Abscess; Lung Abscess; Male; Osteomyelitis; Pancreatitis; Rabbits; Tissue Distribution

1979